Tecelra (afamitresgene autoleucel) / Adaptimmune, US WorldMeds - LARVOL DELTA

Top advances of the year in autologous cellular therapy in melanoma and solid tumors. (PubMed, Cancer) - "Lifileucel, the first Food and Drug Administration-approved tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, demonstrated durable efficacy in the 5-year analysis of the C-144-01 trial, with an objective response rate (ORR) of 31.4% and prolonged responses in a heavily pretreated population...Preferentially expressed antigen in melanoma (PRAME)-targeted T-cell receptor (TCR) T-cell therapy (anzu-cel, IMA203) showed promising activity in a phase 1 study, with ORR of approximately 50% in checkpoint inhibitor refractory melanoma, durable responses, and manageable toxicity, validating PRAME as a high value target across multiple tumor types...OBX-115, an IL-2 independent TIL platform expressing membrane-bound IL-15 regulated by acetazolamide, demonstrated early clinical activity with ORR of 67% in initial phase 1 data...Finally, afamitresgene autoleucel (afami-cel), a MAGE-A4 directed TCR-T therapy, showed durable efficacy in synovial sarcoma and expanding..."

Journal • Review • Melanoma • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma • IL15 • MAGEA4 • PRAME

Autologous T cell therapy for MAGE-A4 solid cancers in HLA-A*02 patients: a phase 1 trial. (PubMed, Nat Med) - P1 | "In addition, afami-cel has an acceptable benefit-risk profile, with early and durable responses, especially in patients with metastatic SS. Although the small trial size limits conclusions that can be drawn, the results warrant further testing in larger studies."

Journal • P1 data • Head and Neck Cancer • Hematological Disorders • Inflammation • Melanoma • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • Synovial Sarcoma • HLA-A • IFNG • MAGEA4

Pooled analyses of clinical outcomes with afamitresgene autoleucel (afami-cel) in metastatic synovial sarcoma. (ASCO 2026) - P1, P2 | " Pts who were HLA-A*02 positive with previously treated, advanced SyS positive for MAGE-A4 received afami-cel after lymphodepleting chemotherapy containing fludarabine and cyclophosphamide... As of May 2025, 153 pts with advanced SyS received afami-cel (1.00 –9.99×109 MAGE-A4 TCR positive T cells)...All pts received prior anthracycline and/or ifosfamide therapy and received a median of 2 prior lines of therapy (range: 1–12)... To the best of our knowledge, this is the largest dataset of T-cell therapy treated pts with advanced SyS. The magnitude of ORR supported by DOR demonstrated with afami-cel treatment is considered clinically meaningful in this rare pt population with a poor prognosis and limited effective therapies. CRS and cytopenias were common and manageable."

Clinical • Clinical data • IO biomarker • Metastases • Constipation • Cough • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Leukopenia • Melanoma • Neutropenia • Respiratory Diseases • Sarcoma • Solid Tumor • Synovial Sarcoma • CD4 • CD8 • HLA-A • MAGEA4

FINAL ANALYSIS FROM SPEARHEAD-1 COHORT 1 OF AFAMITRESGENE AUTOLEUCEL (“AFAMI-CEL” [FORMERLY ADP-A2M4]) IN ADVANCED SYNOVIAL SARCOMA AND MYXOID/ROUND CELL LIPOSARCOMA (CTOS 2022) - No abstract available

Liposarcoma • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. (PubMed, Lancet) - P1, P2 | "Afami-cel treatment resulted in durable responses in heavily pre-treated patients with HLA-A*02 and MAGE-A4-expressing synovial sarcoma. This study shows that T-cell receptor therapy can be used to effectively target solid tumours and provides rationale to expand this approach to other solid malignancies."

Journal • Metastases • P2 data • Hematological Disorders • Leukopenia • Liposarcoma • Neutropenia • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma • HLA-A • MAGEA4

Phase 1 study results with PRAME-directed T-cell receptor (TCR) T-cell therapies in synovial sarcoma. (ASCO 2026) - P1/2 | "Results include 1 pt who received 3 sequential TCR T-cell therapies: the MAGE-A4-targeted afamitresgene-autoleucel (BOR: SD; PFS: 21.4 mos), PRAME-targeted anzu-cel (BOR: cPR; PFS: 24.4 mo), and IMA203CD8 (BOR: cPR; PFS ongoing at 24.4 mo). PRAME-directed TCR T-cell therapies exhibited a safety profile consistent with previous observations, and despite low doses, promising antitumor activity with durable responses that deepened over time in pts with SS. These results warrant further investigation."

P1 data • Sarcoma • Solid Tumor • Synovial Sarcoma • CD4 • CD8 • HLA-A • IL2 • MAGEA4 • PRAME

The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions. (PubMed, Hum Vaccin Immunother) - "Overcoming challenges such as immunosuppressive TME, antigen escape, lack of T-cell persistence, and off-target toxicities is crucial to improving outcomes for sarcoma patients. This review summarizes the evolution of cellular therapies,ongoing research, challenges, and future directions in this field."

Journal • Review • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma • CD276 • HER-2 • MAGEA4 • PRAME

USWM CT, LLC (US WorldMeds) announced that the…FDA has granted full approval of TECELRA (afamitresgene autoleucel) and expanded its indication to include pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy… (PRNewswire) - "Administered as a single infusion, TECELRA became the first engineered T-cell therapy for a solid tumor cancer to receive accelerated FDA approval in the United States, granted in August 2024....The full FDA approval and expanded indication for TECELRA was based on results of the SPEARHEAD-1 study (Cohorts 1, 2 and 3), an open-label, single-arm clinical study, which included 137 patients."

FDA approval • Synovial Sarcoma

Synovial sarcoma misdiagnosis and potential utility of NGS testing patient identification for autologous T cell therapy: Retrospective analysis of Tempus database. (ASCO 2026) - "Commercial NGS testing may increase identification of pts with SS, which is important for novel T cell therapy eligibility. A low threshold should be considered for diagnosing SS in unusual locations when the SS18 fusion is detected."

Next-generation sequencing • Retrospective data • Brain Cancer • Neurofibrosarcoma • Sarcoma • Solid Tumor • Synovial Sarcoma • HLA-A • MAGEA4 • SS18

Efficacy and safety of engineered TCR-T cell therapy (afami-cel, lete-cel) in pediatric synovial sarcoma. (ASCO 2026) - P1, P1/2, P2 | "Engineered TCR-T cell therapy targeting NY-ESO-1 (lete-cel) or MAGE-A4 (afami-cel) has shown responses and durable responses in the pediatric SyS population. The safety profile in this age group is consistent with that observed in the adult population. TCR-T represents a potential new treatment paradigm for pediatric SyS patients."

Clinical • Hematological Disorders • Pediatrics • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Synovial Sarcoma • CTAG1B • MAGEA4

Cellular Therapies in Solid Tumors: Are We Ready for Primetime? (PubMed, JCO Oncol Pract) - "This landscape shifted significantly in 2024 with US Food and Drug Administration approvals of lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, and afamitresgene autoleucel, an engineered T-cell receptor (TCR) therapy for synovial sarcoma...Early biomarker testing, timely referral to specialized centers, and familiarity with evolving toxicity management frameworks are increasingly critical. Here, we seek to provide a practice-oriented framework for understanding emerging ACT platforms, clinical data, toxicity considerations, and implementation strategies relevant to contemporary solid tumor oncology care."

IO biomarker • Journal • Hematological Disorders • Hematological Malignancies • Melanoma • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma

Advances in cell therapy for solid tumours: European perspective and future directions. (PubMed, Lancet Reg Health Eur) - "The recent US FDA approvals of lifileucel (a TIL therapy for advanced melanoma) and afamitresgene autoleucel (a TCR therapy targeting MAGE-A4 in synovial sarcoma) mark the first regulatory recognition of cell therapies for solid tumours and signal a new era for oncology...Emphasis is placed on emerging innovations like gene-edited and allogeneic therapies, as well as future directions for integrating cell therapies into mainstream oncology. We conclude with recommendations for overcoming barriers related to cost, toxicity management, and equitable access across Europe."

Journal • Review • Hematological Disorders • Hematological Malignancies • Melanoma • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma • MAGEA4

Mutant Selective T-Cell Receptor Therapy for Solid Tumors. (PubMed, Mol Cancer Ther) - "Early successes, such as the FDA approvals of lifileucel and afamitresgene autoleucel, highlight the promise of these approaches, while proof-of-concept clinical studies demonstrate activity of personalized neoantigen-reactive TCRs in advanced solid tumors. Major challenges remain, including safety concerns from off-tumor toxicities and resistance mechanisms such as HLA loss of heterozygosity. Ongoing innovations in target discovery, TCR engineering, and combination strategies aim to overcome these barriers and establish mutant-selective TCR therapy as a viable therapeutic strategy in the treatment of solid tumors."

IO biomarker • Journal • Oncology • Solid Tumor

THE SCALE OF PROLONGED UNCERTAINTY: ESTIMATING U.S. PATIENT POPULATIONS AFFECTED BY OVERDUE ACCELERATED APPROVAL CONFIRMATORY TRIALS (ISPOR 2026) - "The largest estimated eligible prevalent population was for adagrasib in KRAS G12C-mutated metastatic non-small cell lung cancer (~33,700-36,500 patients). As of January 2026, overdue AA confirmatory requirements remain common and include both rare disease and indications affecting tens of thousands of patients. As of January 2026, overdue AA confirmatory requirements remain common and include both rare disease and indications affecting tens of thousands of patients. When confirmatory trials are delayed, questions about the balance of benefit and harm and the value of therapies remain unresolved. This uncertainty affects treatment decisions, resource allocation, and coverage determinations, reinforcing the need for timely completion and clear monitoring of confirmatory studies."

Clinical • Infectious Disease • Lung Cancer • Non Small Cell Lung Cancer • Rare Diseases • Sarcoma • Solid Tumor • Synovial Sarcoma • KRAS

Development of MAGE-A4 IHC 1F9 pharmDx for melanoma-associated antigen 4 (MAGE-A4) detection in FFPE synovial sarcoma specimens for afamitresgene autoleucel therapy (AACR 2025) - "These studies demonstrated high analytical assay performance and observer scoring precision of the MAGE-A4 IHC 1F9 pharmDx assay in SyS and combined with sqNSCLC specimens at MAGE-A4 TIPS (≥ 2+) ≥ 75%."

Lung Cancer • Lung Non-Small Cell Squamous Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma • MAGEA4

Discovery of T cell receptor mimic antibody against MAGE-A4 with single B-cell cloning platform (AACR 2024) - "TCR mimic antibodies also demonstrated antibody dependent cell killing with the potency of sub-nanomolar. In summary, we have generated and extensively characterized a panel of high affinity and selective TCR mimic antibodies against HLA-A*02:01 MAGE-A4 using a newly established single cell cloning platform."

IO biomarker • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Synovial Sarcoma • Urothelial Cancer • HLA-A • MAGEA4 • WT1

Allele-specific HLA LOH frequencies and survival outcomes in cancer: a real-world analysis (AACR 2025) - "For instance, A*02:01-specific LOH was associated with worse survival in CRC (HR 0.5355, 95% CI 0.2991-0.9589), but showed a trend toward improved survival in LUAD (HR 1.342, 95% CI 0.7713-2.336), in all patients treated with any therapy.Our findings highlight that over 90% of cancer cases found in the database are genomically intact at the HLA class I locus, preserving the molecular complex needed for TCR-HLA:driver mutation-based therapies. However, the association of A*02:01-specific LOH with poorer survival in CRC and the opposite trend in LUAD underscores the need for further investigation into allele-specific factors that may influence outcomes across various cancer types, treatment lines, and therapeutic modalities."

Clinical • IO biomarker • Real-world • Real-world evidence • Colorectal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS • TP53

Cell therapy in sarcoma: current landscape and future directions. (PubMed, J Immunother Cancer) - "This constituted only the second approval of a cell therapy in a solid tumor following lifileucel in melanoma and demonstrated the potential of cell therapies in sarcomas...However, the broader application of these therapies is hindered by the lack of targetable sarcoma-restricted immunogenic epitopes, spatiotemporal intratumoral heterogeneity, and a profoundly immunosuppressive tumor microenvironment that impedes effector-cell trafficking, expansion and persistence. While cell therapies hold promise for integration into precision medicine approaches for sarcomas, their successful implementation will require careful evaluation of clinical feasibility, logistical considerations and cost-effectiveness to optimize patient outcomes."

Journal • Review • Melanoma • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma • MAGEA4

CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges. (PubMed, Mol Ther Nucleic Acids) - "Since then, the US FDA has approved nearly 30 new viral gene therapy programs, with notable examples including Zolgensma, Spinraza, Hemgenix, Zynteglo, Lyfgenia, Kymriah, Skysona, and Tecelra...In this review, we examine the range of these therapeutics and their viral carriers, focusing primarily on LVs and AAVs. We provide a snapshot of the current status of the field and highlight some of the current challenges in the clinical application of gene therapy, with particular emphasis on viral CRISPR-Cas-based technologies and their future potential."

Journal • Review • Gene Therapies • Genetic Disorders

AN EVALUATION OF AFAMITRESGENE AUTOLEUCEL FOR THE TREATMENT OF ADVANCED SYNOVIAL SARCOMA AND MYXOID ROUND CELL LIPOSARCOMA. (PubMed, Expert Rev Anticancer Ther) - "However, challenges remain regarding HLA restriction, tumor microenvironment resistance, manufacturing delays and cost. Future efforts should focus on broadening applicability, optimizing combinations, and ensuring equitable access."

Journal • Review • Hematological Disorders • Liposarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Synovial Sarcoma • MAGEA4

Update on pediatric soft tissue sarcomas. (PubMed, Curr Opin Pediatr) - "Pediatric STS are rare and biologically heterogeneous. Genomic advances have refined risk stratification and uncovered therapeutic targets; further progress relies on international collaboration and trials."

IO biomarker • Journal • Review • Alveolar Soft Tissue Sarcoma • Oncology • Pediatrics • Rhabdomyosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Synovial Sarcoma • FOXO1 • MYOD1 • NTRK • TP53

A PHASE II STUDY OF HIGH DOSE IFOSFAMIDE IN METASTATIC/LOCALLY ADVANCED SYNOVIAL SARCOMA FROM A TERTIARY CARE CENTER IN INDIA (CTOS 2025) - "Others treatment options like Anlotinib and cellular therapies like afamitresgene autoleucel are either expensive or not suitable due to very low positivity of HLA-02 in Indian populationAs Indian and international data is lacking, we are doing this phase II study and analyse the effectiveness of this drug in this particular sarcoma type.Primary objective: • To study single agent ifosfamide in relapsed metastatic synovial sarcoma patients as determined by overall response rate (Complete response + Partial Response)Secondary objectives include overall survival, Toxity profiles, Quality of life analysis and median progression free survival Study design: Single arm, Phase II, Simon 2-stage clinical trial Study setting: The study will be conducted at Department of Medical Oncology, BRAIRCH, AIIMS, New Delhi... N/A"

Metastases • P2 data • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma

THE PATTERN.ORG SARCOMA CONSORTIUM: BUILDING A MULTI-INSTITUTIONAL DATA RESOURCE FOR THE SARCOMA RESEARCH COMMUNITY (CTOS 2025) - "Molecularly focused research has led to breakthroughs, notably afami-cel in synovial sarcoma and nab-sirolimus in PEComa... This pilot sarcoma data consortium project combined efforts from RCRF, UNC and PICI. These data offer some preliminary insights into the cohort, but we seek additional partners to facilitate a multi-institutional consortium around sarcoma sample and data collection and sharing. We plan to bring additional institutions in as we expand this resource in the coming year."

Clinical • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma • CTLA4 • PD-1

SINGLE-CELL RNA SEQUENCING OF AFAMITRESGENE AUTOLEUCEL INDICATES MECHANISMS OF PERSISTENCE AND ANTI-TUMOR ACTIVITY (CTOS 2025) - "We hypothesize that MP with T-cell subsets poised for sustained effector function and long-lived memory formation are capable of longer post-infusion persistence, sustaining higher afami-cel pharmacokinetic exposure, and will discuss the gene expression programs underlying these different cellular potentials."

IO biomarker • Liposarcoma • Melanoma • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma • CD4 • MAGEA4

Preclinical Proof of Concept for Decentralized Manufacturing of a MAGE-A4/CD8alpha-Expressing Autologous T-Cell Therapy for Solid Tumors (ASH 2024) - P1, P2 | "We investigated suitability of a decentralized, rapid, and fresh cell manufacturing platform to produce T cells expressing the MAGE-A4 TCR and CD8α co-receptor compared with the established central manufacturing process for uza-cel. Importantly, the GDM platform could significantly reduce total vein-to-vein time for eligible patients from several weeks to ~1 week. The GDM system will be used to supply MAGE-A4/CD8α–expressing T cells for a proof-of-concept clinical trial to assess their safety and efficacy in patients with advanced head and neck cancer."

IO biomarker • Preclinical • Genito-urinary Cancer • Head and Neck Cancer • Melanoma • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma • Urothelial Cancer • CD4 • IFNG • MAGEA4